News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
604,208 Results
Type
Article (36129)
Company Profile (128)
Press Release (567951)
Section
Business (171966)
Career Advice (2725)
Deals (32254)
Drug Delivery (73)
Drug Development (72169)
Employer Resources (156)
FDA (15470)
Job Trends (14463)
News (298848)
Policy (28773)
Tag
Academia (2641)
Alliances (42753)
Alzheimer's disease (1250)
Approvals (15393)
Artificial intelligence (107)
Bankruptcy (279)
Best Places to Work (11916)
Biotechnology (96)
Breast cancer (97)
Cancer (854)
Career advice (2258)
Cell therapy (199)
Clinical research (57115)
Collaboration (313)
Compensation (166)
COVID-19 (2394)
C-suite (77)
Cystic fibrosis (79)
Data (863)
Diabetes (127)
Diagnostics (6334)
Earnings (65660)
Employer resources (137)
Events (98492)
Executive appointments (252)
FDA (15905)
Funding (280)
Gene therapy (144)
GLP-1 (461)
Government (3950)
Healthcare (19649)
Infectious disease (2461)
Inflammatory bowel disease (105)
Interviews (537)
IPO (15913)
Job creations (2857)
Job search strategy (1884)
Layoffs (364)
Legal (6305)
Lung cancer (140)
Manufacturing (140)
Medical device (13759)
Medtech (13764)
Mergers & acquisitions (16431)
Metabolic disorders (296)
Neuroscience (1484)
NextGen Class of 2024 (6694)
Non-profit (4808)
Northern California (1210)
Obesity (157)
Opinion (195)
Patents (91)
People (50385)
Phase I (17708)
Phase II (25355)
Phase III (18966)
Pipeline (200)
Postmarket research (2006)
Preclinical (7238)
Radiopharmaceuticals (247)
Rare diseases (184)
Real estate (4870)
Regulatory (19649)
Research institute (2426)
Resumes & cover letters (448)
Southern California (1095)
Startups (3020)
United States (11572)
Vaccines (481)
Weight loss (103)
Date
Today (88)
Last 7 days (742)
Last 30 days (2775)
Last 365 days (36366)
2024 (30785)
2023 (41283)
2022 (52112)
2021 (57041)
2020 (55570)
2019 (48734)
2018 (36630)
2017 (32102)
2016 (30370)
2015 (35472)
2014 (24630)
2013 (19206)
2012 (20726)
2011 (21532)
2010 (18623)
Location
Africa (752)
Arizona (112)
Asia (35310)
Australia (6289)
California (2678)
Canada (1160)
China (198)
Colorado (120)
Connecticut (121)
Europe (81535)
Florida (393)
Georgia (107)
Illinois (306)
Indiana (179)
Kansas (93)
Maryland (496)
Massachusetts (2229)
Michigan (157)
Minnesota (245)
New Jersey (809)
New York (824)
North Carolina (706)
Northern California (1210)
Ohio (126)
Pennsylvania (739)
South America (1076)
Southern California (1095)
Texas (377)
Utah (84)
Washington State (321)
604,208 Results for "orexo ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Report from Orexo AB’s annual general meeting, 26 April 2024
The annual general meeting in Orexo AB on 26 April 2024 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be five with no deputy board members.
April 26, 2024
·
6 min read
Complete response letters
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Citing the need for another human factor study and more technical data for the final product, the FDA denied approval of Orexo’s nasal spray rescue medication for opioid overdose.
July 17, 2024
·
2 min read
·
Tristan Manalac
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
On March 28, 2024, Orexo AB, successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years.
May 10, 2024
·
2 min read
Policy
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo AB, announces that the United States Patent and Trademark Office has granted another US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
April 17, 2024
·
3 min read
Correction: Notice of Annual General Meeting of Orexo
The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024, at 16.00 pm in Orexo’s facilities at Rapsgatan 7E in Uppsala, Sweden.
March 22, 2024
·
33 min read
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
On March 13, 2024, Orexo AB, announced that the Company intends to redeem early the Company’s existing senior unsecured bonds with maturity in February 2025 .
April 2, 2024
·
2 min read
Orexo and Sobi agree to advance feasibility study with AmorphOX
Orexo AB, announces the company agreed with Swedish Orphan Biovitrum AB to advance the successful exploratory feasibility study initiated last year.
February 12, 2024
·
3 min read
Notice of Annual General Meeting of Orexo - March 15, 2024
The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024, at 16.00 pm in Orexo’s facilities at Rapsgatan 7E in Uppsala, Sweden.
March 15, 2024
·
33 min read
Business
Orexo Q1 2024 Interim Report
Orexo and Sobi agreed to advance feasibility study where AmorphOX® is tested with one of their biomolecules.
May 8, 2024
·
3 min read
Notice of Extraordinary General Meeting in Orexo AB (publ)
Orexo AB, Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.
October 3, 2023
·
6 min read
1 of 60,421
Next
